Head to Head Review: Spyre Therapeutics (NASDAQ:SYRE) and Actinium Pharmaceuticals (NYSE:ATNM)

Spyre Therapeutics (NASDAQ:SYRE) and Actinium Pharmaceuticals (NYSE:ATNM) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Analyst Recommendations

This is a summary of recent recommendations for Spyre Therapeutics and Actinium Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1	1	13	2	2.94
Actinium Pharmaceuticals	0	0	1	0	3.00

Spyre Therapeutics currently has a consensus price target of $110.53, indicating a potential upside of 3.48%. Actinium Pharmaceuticals has a consensus price target of $5.00, indicating a potential upside of 214.47%. Given Actinium Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Actinium Pharmaceuticals is more favorable than Spyre Therapeutics.

Profitability

This table compares Spyre Therapeutics and Actinium Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-35.97%	-27.67%
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

Volatility and Risk

Spyre Therapeutics has a beta of 3.24, meaning that its share price is 224% more volatile than the S&P 500. Comparatively, Actinium Pharmaceuticals has a beta of 0.27, meaning that its share price is 73% less volatile than the S&P 500.

Valuation & Earnings

This table compares Spyre Therapeutics and Actinium Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	N/A	N/A	-$155.20 million	($2.74)	-38.99
Actinium Pharmaceuticals	$35.09 million	1.42	-$48.82 million	$0.36	4.42

Actinium Pharmaceuticals has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

80.4% of Spyre Therapeutics shares are owned by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. 15.7% of Spyre Therapeutics shares are owned by company insiders. Comparatively, 0.9% of Actinium Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Spyre Therapeutics beats Actinium Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company developing antibody-based medicines for inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. Its research focuses on therapies designed to target immune pathways involved in these conditions. The company’s pipeline includes investigational antibodies targeting TL1A, IL-23 and integrin ?4?7, as well as potential combinations of these approaches. Spyre has no approved products, and its candidates remain in development.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. is a biotechnology company focused on developing targeted radiotherapies for patients with hematologic malignancies, particularly those with relapsed or refractory disease. The company’s approach uses monoclonal antibodies to deliver radioactive isotopes directly to cancer cells, with the goal of selectively destroying malignant cells while limiting damage to healthy tissue. Actinium’s leading investigational product is Iomab-B, also known as iodine-131 apamistamab.